Autopsy report · NCT02565147

Bivalirudin Infusion for Ventricular Infarction Limitation

“Futility at the interim analysis.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 78 participants enrolled.
• Results were posted on the registry 2 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

The Medicines Company

Sponsor type

Industry

Conditions

Acute Myocardial Infarction

Interventions

PPCI; Bivalirudin; Heparin

Participants

78

Sites

4

Countries

France, Netherlands

Trials that died the same way

• Sevoflurane and Percutaneous Coronary Intervention by Stent
  “interim analysis suggests futility” (94% match in meaning)
• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
  “The result of a pre-planned interim futility analysis” (89% match in meaning)
• Study of M5049 in DM and PM Participants (NEPTUNIA)
  “Based on interim analyses for futility” (87% match in meaning)
• Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation
  “Interim futility analysis” (87% match in meaning)
• Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
  “Study futility based on the interim analysis” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.